Glaukos to acquire Dose Medical, move into retinal space

Glaukos Corporation has entered into a definitive Agreement and Plan of Merge to acquire Dose Medical Corporation, a developer of microinvasive, bioerodible, sustained-release drug delivery platforms for various retinal diseases.

The acquisition will cost Glaukos $2.5 million in cash plus performance-based consideration upon achievement of certain regulatory approvals and commercial milestones, according to a company press release.

The transaction, which includes all remaining assets and liabilities of Dose Medical, was completed in June and makes the company a wholly owned subsidiary of Glaukos.

Previously, Dose Medical was already a wholly owned subsidiary of Glaukos, but in 2010 it was spun-out as a standalone entity. In 2015, Glaukos acquired the iDose product line and related assets from the company, and in 2017, Glaukos acquired IOP sensor system assets for $5.5 million in cash and up to $9.5 million in performance-based considerations.

1 image with caption 1 col
Glaukos Corporation has entered into a definitive Agreement and Plan of Merge to acquire Dose Medical Corporation, a developer of microinvasive, bioerodible, sustained-release drug delivery platforms for various retinal diseases.
Source: Adobe Stock

“With this acquisition, Glaukos will establish a new R&D retinal program that complements our growing glaucoma franchise and pipeline. We plan to build upon the promising work Dose Medical has already done, while leveraging our unique expertise in disruptive, micro-scale innovation to advance exciting new treatment options for AMD and other retinal diseases,” Thomas Burns, Glaukos president and chief executive officer, said.

Editor’s note: This article has been updated to note that the business transaction is complete.

Glaukos Corporation has entered into a definitive Agreement and Plan of Merge to acquire Dose Medical Corporation, a developer of microinvasive, bioerodible, sustained-release drug delivery platforms for various retinal diseases.

The acquisition will cost Glaukos $2.5 million in cash plus performance-based consideration upon achievement of certain regulatory approvals and commercial milestones, according to a company press release.

The transaction, which includes all remaining assets and liabilities of Dose Medical, was completed in June and makes the company a wholly owned subsidiary of Glaukos.

Previously, Dose Medical was already a wholly owned subsidiary of Glaukos, but in 2010 it was spun-out as a standalone entity. In 2015, Glaukos acquired the iDose product line and related assets from the company, and in 2017, Glaukos acquired IOP sensor system assets for $5.5 million in cash and up to $9.5 million in performance-based considerations.

1 image with caption 1 col
Glaukos Corporation has entered into a definitive Agreement and Plan of Merge to acquire Dose Medical Corporation, a developer of microinvasive, bioerodible, sustained-release drug delivery platforms for various retinal diseases.
Source: Adobe Stock

“With this acquisition, Glaukos will establish a new R&D retinal program that complements our growing glaucoma franchise and pipeline. We plan to build upon the promising work Dose Medical has already done, while leveraging our unique expertise in disruptive, micro-scale innovation to advance exciting new treatment options for AMD and other retinal diseases,” Thomas Burns, Glaukos president and chief executive officer, said.

Editor’s note: This article has been updated to note that the business transaction is complete.